Radiation-induced lung injury

Clinical Pulmonary Medicine

Volumn 13, Issue 4, 2006, Pages 232-242

  Ataya, Samir ^a   Elwing, Jean ^a   Biddinger, Paul ^a   Panos, Ralph J ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Lung injury; Radiation; Radiation pneumonitis

Indexed keywords

AMIFOSTINE; AZATHIOPRINE; CAPTOPRIL; CARVEDILOL; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA; KERATINOCYTE GROWTH FACTOR; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PENTOXIFYLLINE; RECOMBINANT KERATINOCYTE GROWTH FACTOR; STEROID;

APOPTOSIS; CELL DAMAGE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DYSPNEA; FIBROSIS; GENE THERAPY; HISTOGRAM; HISTOPATHOLOGY; HUMAN; INFLAMMATION; KIDNEY INJURY; LIPID PEROXIDATION; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG INJURY; LUNG LAVAGE; LUNG PARENCHYMA; MORBIDITY; NONHUMAN; PATHOGENESIS; RADIATION; RADIATION DOSE; RADIATION PNEUMONIA; RADIOGRAPHY; RESPIRATORY TRACT INFECTION; REVIEW; RISK; RISK FACTOR; SEROLOGY; THORAX; UNSPECIFIED SIDE EFFECT;

EID: 33745926835     PISSN: 10680640     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cpm.0000227598.88431.04     Document Type: Review

References (136)

1. Moulder JE. Post-irradiation approaches to treatment of radiation injuries in the context of radiological terrorism and radiation accidents: a review. Int J Radiat Biol. 2004;80:3-10.
2. Stone HB, Coleman CN, Anscher MS, et al. Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol. 2003;4: 529-536.
3. Maisin JR. The ultrastructure of the lung of mice exposed to a supra-lethal dose of ionizing radiation on the thorax. Radiat Res. 1970;44:545-564.
4. Bai YH, Wang DW, Wang LP, et al. The role of free radicals in the development of radiation interstitial pneumonitis. J Environ Pathol Toxicol Oncol. 1993;12:199-204.
5. Willers H, Dahm-Daphi J, Powell SN. Repair of radiation damage to DNA. Br J Cancer. 2004;90:1297-1301.
6. Zhang Q, Wang Y. Generation of 5-(2′-deoxycytidyl)methyl radical and the formation of intrastrand cross-link lesions in oligodeoxyribonucleotides. Nucleic Acids Res. 2005;33:1593-1603.
7. Fuks Z, Persaud RS, Alfieri A, et al. Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res. 1994;54:2582-2590.
8. Gross NJ. Pulmonary effects of radiation therapy. Ann Intern Med. 1977;86:81-92.
9. Adamson IY, Bowden DH. The type 2 cell as progenitor of alveolar epithelial regeneration. A cytodynamic study in mice after exposure to oxygen. Lab Invest. 1974;30:35-42.
10. Tannock IF, Hayashi S. The proliferation of capillary endothelial cells. Cancer Res. 1972;32:77-82.
11. Jack CI, Cottier B, Jackson MJ, et al. Indicators of free radical activity in patients developing radiation pneumonitis. Int J Radiat Oncol Biol Phys. 1996;34:149-154.
12. Chan C, Goldkorn T. Ceramide path in human lung cell death. Am J Respir Cell Mol Biol. 2000;22:460-468.
13. Lewanski CR, Gullick WJ. Radiotherapy and cellular signalling. Lancet Oncol. 2001;2:366-370.
14. Rubin P, Johnston CJ, Williams JP, et al. A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys. 1995;33:99-109.
15. Hauer-Jensen M, Kong FM, Fink LM, et al. Circulating thrombomodulin during radiation therapy for lung cancer. Radiat Oncol Invest. 1999;7:238-242.
16. Khalil N, O'Connor RN, Unruh HW, et al. Increased production and immunohistochemical localization of transforming growth factor-β in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 1991;5:155-162.
17. Tada H, Ogushi F, Tani K, et al. Increased binding and chemotactic capacities of PDGF-BB on fibroblasts in radiation pneumonitis. Radiat Res. 2003;159:805-811.
18. Calaf GM, Hei TK. Ionizing radiation induces alterations in cellular proliferation and c-myc, c-jun and c-fos protein expression in breast epithelial cells. Int J Oncol. 2004;25:1859-1866.
19. Meeren A, Vandamme M, Squiman C, et al. Inflammatory reaction and changes in expression of coagulation proteins on lung endothelial cells after total-body irradiation in mice. Radiat Res. 2003;160:637-646.
20. Trott KR, Herrmann T, Kasper M. Target cells in radiation pneumopathy. Int J Radiat Oncol Biol Phys. 2004;58:463-469.
21. Morgan GW, Breit SN. Radiation and the lung: a reevaluation of the mechanisms mediating pulmonary injury. Int J Radiat Oncol Biol Phys. 1995;31:361-369.
22. Ruebe CE, Uthe D, Wilfert F, et al. The bronchiolar epithelium as a prominent source of pro-inflammatory cytokines after lung irradiation. Int J Radiat Oncol Biol Phys. 2005;61:1482-1492.
23. Remy J, Wegrowski J, Crechet F, et al. Long-term overproduction of collagen in radiation-induced fibrosis. Radiat Res. 1991;125:14-19.
24. Rubin P, Shapiro DL, Finklestein JN, et al. The early release of surfactant following lung irradiation of alveolar type II cells. Int J Radiat Oncol Biol Phys. 1980;6:75-77.
25. Maisin JR. The influence of radiation on blood vessels and circulation. Chapter 3. Ultrastructure of the vessel wall. Curr Top Radiat Res Q. 1974;10:29-57.
26. Phillips TL, Margolis L. Radiation pathology and the clinical response of the lung and esophagus. Front Radiat Ther Oncol. 1972;6:49-54.
27. Phillips TL. An ultrastructural study of the development of radiation injury in the lung. Radiology. 1966;8:49-54.
28. Kasper M, Haroske G. Alterations in the alveolar epithelium after injury leading to pulmonary fibrosis. Histol Histopathol. 1996;11:463-483.
29. Mollis M, van Beuningen D. Radiation injury to the lungs: experimental studies, observations after radiotherapy and total body irradiation prior to bone marrow transplant. Radiopathology of Organs and Tissues. 1991:369-404.
30. Goldenberg VE, Warren S, Chute R, et al. Radiation pneumonitis in single and parabiotic rats. I. Short term effects of supralethal total body irradiation. Lab Invest. 1968;18:215-226.
31. Madrazo A, Suzuki Y, Churg J. Radiation pneumonitis. Ultrastructural changes in the pulmonary alveoli following high doses of radiation. Arch Pathol. 1973;96:262-268.
32. Watanabe S, Watanabe K, Oishi T, et al. Mast cells in the rat alveolar septa undergoing fibrosis after ionizing irradiation. Ultrastructural and histochemical studies. Lab Invest. 1974;31:555-567.
33. Adamson IY, Bowden DH, Wyatt JP. A pathway to pulmonary fibrosis: an ultrastructural study of mouse and rat following radiation to the whole body and hemithorax. Am J Pathol. 1970;58:481-498.
34. Leroy EP, Liebner EJ, Jensik RJ. The ultrastructure of canine alveoli after supervoltage irradiation of the thorax. I. Lesions of the latent period. Lab Invest. 1966;15:1544-1558.
35. Movsas B, Raffin TA, Epstein AH, et al. Pulmonary radiation injury. Chest. 1997;111:1061-1076.
36. Abratt RP, Morgan GW. Lung toxicity following chest irradiation in patients with lung cancer. Lung Cancer. 2002;35:103-109.
37. Kaufman J, Komorowski R. Bronchiolitis obliterans. A new clinical-pathologic complication of irradiation pneumonitis. Chest. 1990;97: 1243-1244.
38. Crestani B, Kambouchner M, Soler P, et al. Migratory bronchiolitis obliterans organizing pneumonia after unilateral radiation therapy for breast carcinoma. Eur Respir J. 1995;8:318-321.
39. Martin C, Romero S, Sanchez-Paya J, et al. Bilateral lymphocytic alveolitis: a common reaction after unilateral thoracic irradiation. Eur Respir J. 1999;13:727-732.
40. Epler GR, Colby TV, McLoud TC, et al. Bronchiolitis obliterans organizing pneumonia. N Engl J Med. 1985;312:152-158.
41. Crestani B, Valeyre D, Roden S, et al. Bronchiolitis obliterans organizing pneumonia syndrome primed by radiation therapy to the breast. Am J Respir Crit Care Med. 1998;158:1929-1935.
42. Bayle J-Y, Nesme P, Béjui-Thivolet F, et al. Migratory organizing pneumonitis 'primed' by radiation therapy. Eur Respir J. 1995;8:322-326.
43. Nambu A, Araki T, Ozawa K, et al. Bronchiolitis obliterans organizing pneumonia after tangential beam irradiation to the breast: discrimination from radiation pneumonitis. Radiat Med. 2002;20:151-154.
44. Epler GR. Bronchiolitis obliterans organizing pneumonia. Arch Intern Med. 2001;16:158-164.
45. Roberts CM, Foulcher E, Zaunders JJ, et al. Radiation pneumonitis: a possible lymphocyte-mediated hypersensitivity reaction. Ann Intern Med. 1993;118:696-700.
46. Roach M III, Gandara DR, You HS, et al. Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol. 1995;13:2606-2612.
47. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341-1346.
48. Quon H, Shepherd FA, Payne DG, et al. The influence of age on delivery, tolerance, and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys. 1999;43:39-45.
49. Robnett TJ, Machtay M, Vines EF. Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys. 2000;48:89-94.
50. Inoue A, Kunitoh H, Sekine I, et al. Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis. Int J Radiat Oncol Biol Phys. 2001;49:649-655.
51. Rancati T, Ceresoli GL, Gagliardi G, et al. Factors predicting radiation pneumonitis in lung cancer patients a retrospective study. Radiother Oncol. 2003;67:275-283.
52. 30 and transforming growth factor β. Int J Radiat Oncol Biol Phys. 2001;50:899-908.
53. Hara R, Itami J, Komiyama T, et al. Serum levels of KL-6 for predicting the occurrence of radiation pneumonitis after stereotactic radiotherapy for lung tumors. Chest. 2004;125:340-344.
54. Johanson S, Bjermer L, Franzen L, et al. Effects of ongoing smoking on the development of radiation induced pneumonitis in breast cancer and oesophagus cancer patients. Radiol Oncol. 1998;49:41-47.
55. Hernando ML, Marks LB, Bentel GC, et al. Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys. 2001;51:650-659.
56. Fryer CJ, Fitzpatrick PJ, Rider WD, et al. Radiation pneumonitis: experience following a single dose of radiation. Int J Radiat Oncol Biol Phys. 1978;4:931-938.
57. Marks LB. Dosimetric predictors of radiation-induced lung injury. Int J Radiat Oncol Biol Phys. 2002;54:313-316.
58. Tsujino K, Hirota S, Endo M, et al. Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys. 2003;55:110-115.
59. Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1999;45:323-329.
60. Yamada M, Kudoh S, Hirata K, et al. Risk factors of pneumonitis following chemoradiotherapy for lung cancer. Eur J Cancer. 1998;34: 71-75.
61. Taghian AG, Assaad SI, Niemierko A, et al. Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst. 2001;93:1806-1811.
62. Monson JM, Stark P, Reilly JJ, et al. Clinical radiation pneumonitis and radiographic changes after thoracic radiation therapy for lung carcinoma. Cancer. 1998;82:842-850.
63. Theuws JCM, Wagenaar AC, Boersma LJ, et al. Dose-effect relations for early local pulmonary injury after irradiation for malignant lymphoma and breast cancer. Radiother Oncol. 1998;48:33-43.
64. Ma LD, Taylor GA, Wharam MD, et al. 'Recall' pneumonitis: Adriamycin potentiation of radiation pneumonitis in two children. Radiology. 1993;187:465-467.
65. Abratt RP, Morgan GW, Silvestri G, et al. Pulmonary complications of radiation therapy. Clin Chest Med. 2004;25:167-177.
66. Abratt RP, Willcox PA. The effect of irradiation on lung function and perfusion in patients with lung cancer. Int J Radiat Oncol Biol Phys. 1995;31:915-919.
67. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988;93:580-586.
68. Takahashi H, Imai Y, Fujishima T, et al. Diagnostic significance of surfactant proteins A and D in sera from patients with radiation pneumonitis. Eur Respir J. 2001;17:481-487.
69. Nakayama Y, Makino S, Fukuda Y. Activation of lavage lymphocytes in lung injuries caused by radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys. 1996;34:459-467.
70. Anscher MS, Kong FM, Andrews K, et al. Plasma transforming growth factor β1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys. 1998;41:1029-1035.
71. Anscher MS, Kong FM, Marks LB, et al. Changes in plasma transforming growth factor after β 1 during radiotherapy and the risk of symptomatic radiation-induced pneumonitis. Int J Radiat Oncol Biol Phys. 1997;37:253-258.
72. Bai YH, Wang DW, Cui XM, et al. Expression of transforming growth factor β in radiation interstitial pneumonitis. J Environ Pathol Toxicol Oncol. 1997;16:15-20.
73. Novakava-Jiresova A, van Gameren MM, Coppes RP, et al. Transforming growth factor-β plasma dynamics and post-irradiation lung injury in lung cancer patients. Radiother Oncol. 2004;71:183-189.
74. Goto K, Kodama T, Sekine I, et al. Serum levels of KL-6 are useful biomarkers for severe radiation pneumonitis. Lung Cancer. 2001;34: 141-148.
75. Ryusuke H, Itami J, Komiyama T, et al. Serum Levels of KL-6 for predicting the occurrence of radiation pneumonitis after stereotactic radiotherapy for lung tumors. Chest. 2004;125:340-344.
76. Cordier JF, Mornex JF, Lasne Y, et al. Bronchoalveolar lavage in radiation pneumonitis. Bull Eur Physiopathol Respir. 1984;20:369-374.
77. Barthelemy-Brichangt N, Bosquee L, Cataldo D, et al. Increased IL-6 and TGF-β 1 concentrations in bronchoalveolar lavage fluid associated with thoracic radiotherapy. Int J Radiat Oncol Biol Phys. 2004;58:758-767.
78. De Jaeger K, Seppenwoolde Y, Boersma LJ, et al. Pulmonary function following high-dose radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2003;55:1331-1340.
79. Miller KL, Zhou SM, Barrier RC Jr, et al. Long-term changes in pulmonary function tests after definitive radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys. 2003;56:611-615.
80. Choi YW, Munden RF, Erasmus JJ, et al. Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis. Radiographics. 2004;24:985-997.
81. Lindell RM, Hartman TE. Chest imaging in iatrogenic respiratory disease. Clin Chest Med. 2004;25:15-24.
82. Park KJ, Chung JY, Chun MS, et al. Radiation-induced lung disease and the impact of radiation methods on imaging features. Radiographics. 2000;20:83-98.
83. Gross NJ, Narine KR, Wade R. Protective effect of corticosteroids on radiation pneumonitis in mice. Radiat Res. 1988;113:112-119.
84. Arbetter KR, Prakash UB, Tazelaar HD, et al. Radiation-induced pneumonitis in the 'nonirradiated' lung. Mayo Clin Proc. 1999;74:743-744.
85. Prakash UBS. Radiation-induced injury in the 'nonirradiated' lung. Eur Respir J. 1999;13:715-717.
86. King TE Jr. BOOP: an important cause of migratory pulmonary infiltrates? Eur Respir J. 1995;8:193-195.
87. Kwok E, Chan CK. Corticosteroids and azathioprine do not prevent radiation-induced lung injury. Can Respir J. 1998;5:211-214.
88. Magana E, Crowell RE. Radiation pneumonitis successfully treated with inhaled corticosteroids. South Med J. 2003;96:521-524.
89. Muraoka T, Bandoh S, Fujita J, et al. Corticosteroid refractory radiation pneumonitis that remarkably responded to cyclosporin A. Intern Med. 2002;41:730-733.
90. McCarty MJ, Lillis P, Vukelja SJ. Azathioprine as a steroid-sparing agent in radiation pneumonitis. Chest. 1996;109:1397-1400.
91. Milas L, Nishiguchi I, Hunter N, et al. Radiation protection against early and late effects of ionizing irradiation by the prostaglandin inhibitor indomethacin. Adv Space Res. 1992;12:265-271.
92. Gross NJ, Holloway NO, Narine KR. Effects of some nonsteroidal anti-inflammatory agents on experimental radiation pneumonitis. Radiat Res. 1991;127:317-324.
93. Moulder JE, Fish BL, Cohen EP. Angiotensin II receptor antagonists in the treatment and prevention of radiation nephropathy. Int J Radiat Biol. 1998;73:415-421.
94. Cohen EP, Molteni A, Hill P. Captopril preserves function and ultrastructure in experimental radiation nephropathy. Lab Invest. 1996;75: 349-360.
95. Ward WF, Kim YT, Molteni A, et al. Radiation-induced pulmonary endothelial dysfunction in rats: modification by an inhibitor of angiotensin converting enzyme. Int J Radiat Oncol Biol Phys. 1988;15:135-140.
96. Ali SM, Laping NJ, Fredrickson TA, et al. Angiotensin-converting enzyme inhibition attenuates proteinuria and renal TGF-β 1 mRNA expression in rats with chronic renal disease. Pharmacology. 1998;57: 20-27.
97. Zoja C, Abbate M, Corna D, et al. Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-β in experimental mesangioproliferative glomerulonephritis. Am J Kidney Dis. 1998;31:453-463.
98. Ward WF, Molteni A, Kim YT. Structure-function analysis of angiotensin-converting enzyme inhibitors as modifiers of radiation-induced pulmonary endothelial dysfunction in rats. Br J Radiol. 1989;62:348-354.
99. Ward WF, Lin PJ, Wong PS, et al. Radiation pneumonitis in rats and its modification by the angiotensin-converting enzyme inhibitor captopril evaluated by high-resolution computed tomography. Radiat Res. 1993;135:81-87.
100. Strieter RM, Remick DG, Ward PA, et al. Cellular and molecular regulation of tumor necrosis factor-α production by pentoxifylline. Biochem Biophys Res Commun. 1988;30:155:1230-1236.
101. Stephens KE, Ishizaka A, Larrick JW, et al. Tumor necrosis factor causes increased pulmonary permeability and edema. Comparison to septic acute lung injury. Am Rev Respir Dis. 1988;137:1364-1370.
102. Stelzer KJ, Koh WJ, Peterson LM, et al. Effect of high-dose pentoxifylline on acute radiation-induced lung toxicity in a rat lung perfusion model. Int J Radiat Oncol Biol Phys. 1996;34:111-115.
103. Ward WF, Kim YT, Molteni A, et al. Pentoxifylline does not spare acute radiation reactions in rat lung and skin. Radiat Res. 1992;129: 107-111.
104. Osterreicher J, Mokry J, Navratil L. The alveolar septal thickness and type II pneumocytes number in irradiated lungs, time expression and the effect of pentoxifylline. Acta Medico (Hradec Kralove). 2001;44: 15-19.
105. Jonsson OE, Bjermer L, Denekamp J. Perivascular cell protection in vivo and increased cell survival in vitro by the antihypertensive agent carvedilol following radiation. Eur J Cancer. 1999;35:1268-1273.
106. Dubrawsky C, Dubravsky NB, Withers HR. The effect of colchicine on the accumulation of hydroxyproline and on lung compliance after irradiation. Radiat Res. 1978;73:111-120.
107. Ward WF, Shih-Hoellwarth A, Tuttle RD. Collagen accumulation in irradiated rat lung: modification by D-penicillamine. Radiology. 1983; 146:533-537.
108. Rabbani ZN, Anscher MS, Zhang X, et al. Soluble TGFβ type II receptor gene therapy ameliorates acute radiation-induced pulmonary injury in rats. Int J Radiat Oncol Biol Phys. 2003;57:563-572.
109. Nishioka A, Ogawa Y, Mima T, et al. Histopathologic amelioration of fibroproliferative change in rat irradiated lung using soluble transforming growth factor-β (TGF-β) receptor mediated by adenoviral vector. Int J Radiat Oncol Biol Phys. 2004;58:1235-1241.
110. Chen L, Brizel DM, Rabbani ZH, et al. The protective effect of recombinant human keratinocyte growth factor on radiation-induced pulmonary toxicity in rats. Int J Radiat Oncol Biol Phys. 2004;60: 1520-1529.
111. Takeoka M, Ward WF, Pollack H, et al. Keratinocyte growth factor facilitates repair of radiation-induced DNA damage in alveolar epithelial cells. Am J Physiol Lung Cell Mol Biol. 1997;272:L1174-L1180.
112. Ware LB. Keratinocyte growth factor as an epithelial protective agent: where do we stand? Int J Radiat Oncol Biol Phys. 2004;60:1345-1346.
113. Vujaskovic Z, Feng QF, Rabbani ZN, et al. Assessment of the protective effect of amifostine on radiation-induced pulmonary toxicity. Exp Lung Res. 2002;28:577-590.
114. Uzal C, Durmus-Altun G, Caloglu M, et al. The protective effect of amifostine on radiation-induced acute pulmonary toxicity: detection by (99m)Tc-DTPA transalveolar clearances. Int J Radiat Oncol Biol Phys. 2004;60:564-569.
115. Komaki R, Lee JS, Kaplan B, et al. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. Semin Radiol Oncol. 2002;12:46-49.
116. Komaki R, Lee JS, Milas L, et al. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys. 2004;58:1369-1377.
117. Antonadou D. Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer. Semin Radiat Oncol. 2002;12:50-58.
118. Antonadou D, Throuvalas N, Petridis A, et al. Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2003;57:402-408.
119. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000;18:3339-3345. Erratum in J Clin Oncol. 2000;18:4110-4111.
120. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol. 1996;14:2101-2112.
121. Wim JF, van der Vijgh WJ, Peters GJ. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine. Semin Oncol. 1994;21:S2-S7.
122. Calabro-Jones PM, Aguilera JA, Ward JF, et al. Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Res. 1988;48:3634-3640.
123. Ozturk B, Egehan I, Atavci S, et al. Pentoxifylline in prevention of radiation-induced lung toxicity in patients with breast and lung cancer: a double-blind randomized trial. Int J Radiat Oncol Biol Phys. 2004; 58:213-219.
124. Pagel J, Mohorn M, Kloetzer KH, et al. The inhalation versus systemic prevention of pneumonitis during thoracic irradiation. Strahlenther Onkol. 1998;174:25-29.
125. Wang LW, Fu XL, Clough R, et al. Can angiotensin-converting enzyme inhibitors protect against symptomatic radiation pneumonitis? Radiat Res. 2000;153:405-410.
126. Lind PA, Marks LB, Jamieson TA, et al. Predictors for pneumonitis during locoregional radiotherapy in high-risk patients with breast carcinoma treated with high-dose chemotherapy and stem-cell rescue. Cancer. 2002;94:2821-2829.
127. Claude L, Pérol D, Ginestet C, et al. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small cell cancer: clinical and dosimetric factors analysis. Radiother Oncol. 2004;71:175-181.
128. Wennberg B, Gagliardi G, Sundbom L, et al. Early response of lung in breast cancer irradiation: radiologic density changes measured by CT and symptomatic radiation pneumonitis. Int J Radiat Oncol Biol Phys. 2002;52:1196-1206.
129. Muryama S, Akamine T, Sakai S, et al. Risk factor of radiation pneumonitis. Assessment with velocity-encoded cine magnetic resonance imaging of pulmonary artery. J Comput Assist Tomogr. 2004; 28:204-208.
130. Segawa Y, Takigawa N, Kataoka M. Risk factors for development of radiation pneumonitis following radiation therapy with or without chemotherapy for lung cancer. In J Radiat Oncol Biol Phys. 1997;39:91-98.
131. Oetzel D, Schraube P, Hensley F, et al. Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis. Int J Radiat Oncol Biol. 1995;33:445-460.
132. Kwa SLS, Lebesque JV, Theuws JCM, et al. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys. 1998;42:1-9.
133. Jenkins P, D'Amico K, Benstead K, et al. Radiation pneumonitis following treatment of non-small-cell lung cancer with continuous hyperfractionated accelerated radiotherapy (CHART). Int J Radiat Oncol Biol Phys. 2003;56:360-366.
134. Castellino RA, Glatstein E, Turbow MM, et al. Latent radiation injury of lungs or heart activated by steroid withdrawal. Ann Intern Med. 1974;80:593-599.
135. Pezner RD, Gertrand M, Cecchi GR, et al. Steroid-withdrawal radiation pneumonitis in cancer patients. Chest. 1984;85:816-817.
136. National Cancer Institute. Common terminology criteria for adverse events v3. 0 (CTCAE). Available at: ctep.cancer.gov/reporting/ctc.html Accessed April 2005.